Several studies have reported different, in some cases, opposing transcriptional responses to activation of the canonical TGF-β/Smad2 pathway versus the alternative TGF-β/Smad1/Smad2 signal in normal and cancer cells [53]–[55]. The gene discussed is SMAD2; the disease is cancer.